Efforts made by the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) in determining the clinical significance of sequence variants in BRCA1, BRCA2, and other known or suspected breast cancer genes represent an excellent initiative to overcome this challenge and will permit the reclassification of this mutation in order to avoid misdiagnosis and over treatment of breast cancer patients all over the world (Nielsen et al., 2018). This evidence concerns the gene BRCA1 and breast cancer.